ArticleJournal of diabetes investigation2014

Randomized, placebo-controlled, double-blind glycemic control trial of novel sodium-dependent glucose cotransporter 2 inhibitor ipragliflozin in Japanese patients with type 2 diabetes mellitus.

Atsunori Kashiwagi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.